

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AK MEDICAL HOLDINGS LIMITED**

**愛康醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1789)**

## **VOLUNTARY ANNOUNCEMENT CERTIFICATION BY NMPA**

This announcement is made by AK Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep its shareholders and potential investors informed of the latest business development of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Group obtained the certification for the Trauma Custom Bridge (“**TCBridge**”) Class III medical devices approved by the National Medical Products Administration (“**NMPA**”) of the People’s Republic of China (the “**PRC**”) on 30 March 2023.

The approved TCBridge of the Group is manufactured by titanium alloy material through additive manufacturing technology, and matched with the anatomic structure of the patient. TCBridge is used for reconstruction treatment of large segment bone defects caused by trauma, tumor, infection, osteomyelitis. Based on the Group’s Physician-Technician Interaction Platform, the product provides preoperative planning, Physician-Technician interaction, 3D printing customized design and manufacturing processing, and will finally be delivered to the clinic to complete the surgery. The product and its supporting technical process can assist doctors to complete the repair and reconstruction of complex large segmental bone defects of the limbs caused by a variety of reasons, helping patients to restore the anatomical and mechanical structure of the limb bones, regaining health and restoring normal work and life, and will benefit more patients.

TCBridge system is based on Innovative Customised Orthopedic Solution (“**ICOS**”) structure, fully reflecting the advantages of 3D printing digital manufacturing technology. TCBridge products are delivered in full accordance with the ICOS design process, designed to guarantee the safety and efficiency of clinical surgery, and will ultimately achieve functional and biomechanical reconstruction of the patient’s extremity after a large segment of bone defect.

As a technological leader in the domestic orthopaedic industry, the Group continues to innovate in research and development, continuously leading the development of domestic orthopedic field. In 2015, the Group was the first to apply 3D printing technology to the field of orthopaedics in China, and provided personalised solutions to patients through Physician-Technician Interaction Platform. From the launch of 3D printing standardized products to characteristic customization products represented by TCBridge, the results of ICOS orthopedic trauma customization platform is officially achieved, and the Group's 3D printing solutions is further enriched.

By Order of the Board  
**AK Medical Holdings Limited**  
**Li Zhijiang**  
*Chairman*

Hong Kong, 4 April 2023

*As at the date of this announcement, the Board comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive directors, Dr. Wang David Guowei as non-executive director, and Mr. Kong Chi Mo, Dr. Li Shu Wing David and Mr. Eric Wang as independent non-executive directors.*